208175-71-7Relevant academic research and scientific papers
CRYSTALLINE FORMS OF N-(4-(4-(CYCLOPROPYLMETHYL) PIPERAZINE-1-CARBONYL)PHENYL)QUINOLINE-8-SULFONAMIDE
-
Paragraph 00170, (2019/06/11)
Provided herein are amorphous and crystalline hemisulfate salt forms of the formula (I). Also provided are pharmaceutical compositions comprising the amorphous and crystalline hemisulfate salt forms, methods for their manufacture, and uses thereof for tre
Methods of using pyruvate kinase activators
-
Page/Page column 67; 68, (2016/08/23)
Described herein are methods for using compounds that activate pyruvate kinase.
Pyruvate kinase activators for use in therapy
-
Page/Page column 80, (2016/08/29)
Described herein are methods for using compounds that activate pyruvate kinase.
THERAPEUTIC COMPOUNDS AND COMPOSITIONS
-
Page/Page column 16; 17, (2012/07/14)
Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer.
NOVEL N- (4- (AZETIDINE - 1 - CARBONYL) PHENYL) - (HETERO - ) ARYLSULFONAMIDE DERIVATIVES AS PYRUVATE KINASE M2 (PMK2) MODULATORS
-
Page/Page column 40, (2012/06/30)
Compounds of general Formula (I), and compositions comprising compounds of general formula I that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of canc
THERAPEUTIC COMPOUNDS AND COMPOSITIONS
-
Page/Page column 89, (2011/01/05)
Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer.
Benzamidoaldehydes and their use as cysteine protease inhibitors
-
, (2008/06/13)
Compounds of the formula where R1, R2, R3, X and n are as defined in the description, are inhibitors of cysteine protease.
